SK15422002A3 - Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou - Google Patents
Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou Download PDFInfo
- Publication number
- SK15422002A3 SK15422002A3 SK1542-2002A SK15422002A SK15422002A3 SK 15422002 A3 SK15422002 A3 SK 15422002A3 SK 15422002 A SK15422002 A SK 15422002A SK 15422002 A3 SK15422002 A3 SK 15422002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- day
- dose
- galantamine
- weeks
- followed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| PCT/EP2001/003553 WO2001074339A2 (fr) | 2000-04-03 | 2001-03-28 | Utilisation de la galantamine dans le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK15422002A3 true SK15422002A3 (sk) | 2003-04-01 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1542-2002A SK15422002A3 (sk) | 2000-04-03 | 2001-03-28 | Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (fr) |
| JP (1) | JP2003528913A (fr) |
| KR (1) | KR20020086911A (fr) |
| CN (1) | CN1430514A (fr) |
| AU (2) | AU2001265844B2 (fr) |
| BG (1) | BG107093A (fr) |
| BR (1) | BR0109770A (fr) |
| CA (1) | CA2310926C (fr) |
| CZ (1) | CZ20023543A3 (fr) |
| EE (1) | EE200200554A (fr) |
| HR (1) | HRP20020778A2 (fr) |
| HU (1) | HUP0300566A3 (fr) |
| IL (1) | IL152061A0 (fr) |
| MX (1) | MXPA02009777A (fr) |
| NO (1) | NO20024746L (fr) |
| PL (1) | PL361272A1 (fr) |
| RU (1) | RU2002129298A (fr) |
| SK (1) | SK15422002A3 (fr) |
| WO (1) | WO2001074339A2 (fr) |
| ZA (1) | ZA200207935B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| ES2293287T3 (es) * | 2003-07-25 | 2008-03-16 | F. Hoffmann-La Roche Ag | Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos. |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| JP5647099B2 (ja) | 2008-03-27 | 2014-12-24 | チェイス・ファーマスーティカルズ・コーポレーション | 認知症を治療するための使用及び組成物 |
| WO2013160728A1 (fr) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Composés à double ciblage pour le traitement de la maladie d'alzheimer |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| WO2016187339A1 (fr) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | Clairance de galantamine d'amyloides |
| WO2023036105A1 (fr) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | Méthode de traitement d'une maladie neurodégénérative |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| US7939522B1 (en) | 1998-11-23 | 2011-05-10 | Bonnie M Davis | Dosage formulations for acetylcholinesterase inhibitors |
| AU775914B2 (en) * | 1998-12-24 | 2004-08-19 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
| CA2310950C (fr) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | Posologie de galantamine efficace qui reduit les effets secondaires |
| CA2310990A1 (fr) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/fr not_active Expired - Lifetime
-
2001
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/fr not_active Application Discontinuation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 EP EP01943200A patent/EP1272192A2/fr not_active Withdrawn
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200207935B (en) | 2004-01-30 |
| EP1272192A2 (fr) | 2003-01-08 |
| NO20024746L (no) | 2002-11-28 |
| MXPA02009777A (es) | 2003-03-27 |
| KR20020086911A (ko) | 2002-11-20 |
| WO2001074339A2 (fr) | 2001-10-11 |
| WO2001074339A3 (fr) | 2002-09-12 |
| RU2002129298A (ru) | 2004-03-27 |
| AU2001265844B2 (en) | 2005-04-14 |
| CN1430514A (zh) | 2003-07-16 |
| HRP20020778A2 (en) | 2004-04-30 |
| PL361272A1 (en) | 2004-10-04 |
| NO20024746D0 (no) | 2002-10-02 |
| HUP0300566A3 (en) | 2004-10-28 |
| BR0109770A (pt) | 2003-02-04 |
| BG107093A (bg) | 2003-06-30 |
| JP2003528913A (ja) | 2003-09-30 |
| CA2310926C (fr) | 2002-10-15 |
| IL152061A0 (en) | 2003-05-29 |
| EE200200554A (et) | 2004-04-15 |
| CZ20023543A3 (cs) | 2003-03-12 |
| CA2310926A1 (fr) | 2000-10-04 |
| AU6584401A (en) | 2001-10-15 |
| HUP0300566A2 (hu) | 2003-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tandon et al. | Muscarinic cholinergic hyperactivity in schizophrenia: relationship to positive and negative symptoms | |
| Santosh et al. | Psychopharmacotherapy in children and adults with intellectual disability | |
| JP2018002738A (ja) | ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物 | |
| CA2310950C (fr) | Posologie de galantamine efficace qui reduit les effets secondaires | |
| KR20010102460A (ko) | 운동 유발 천식의 치료 방법 | |
| US20220184074A1 (en) | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor | |
| SK15422002A3 (sk) | Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou | |
| AU2022252766A1 (en) | Treatment of hand eczema | |
| Pollock et al. | Antipsychotics in older patients: a safety perspective | |
| JPH0667842B2 (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| KR20010102459A (ko) | Ｃｏｐｄ의 치료 방법 | |
| US20060172993A1 (en) | Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease | |
| RU2818678C2 (ru) | Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона | |
| Thornton | Sleep aids and sedatives | |
| KR20230136142A (ko) | 치료 방법 | |
| KORSANTIA et al. | PEMPHIGUS VULGARIS, CURRENT STATUS AND PROSPECTS | |
| US20210023091A1 (en) | Treatment of conditions associated with myotonic dystrophy | |
| TW202333705A (zh) | 治療與阿茲海默症相關之激越的方法 | |
| AU2022228417A1 (en) | Use of luvadaxistat for the treatment of cognitive impairment | |
| CA3144067A1 (fr) | Lemborexant pour le traitement de problemes de sommeil | |
| Walsh | Antihistamines (H1 receptor antagonists) | |
| Allegaert et al. | PROCEEDINGS OF THE DUTCH SOCIETY OF CLINICAL PHARMACOLOGY AND BIOPHARMACY MEETING OF OCTOBER 4TH 2005 |